Filter Results
:
(119)
Show Results For
-
All HBS Web
(600)
- Faculty Publications (119)
Show Results For
-
All HBS Web
(600)
- Faculty Publications (119)
Diseases
→
Page 1 of
119
Results
→
- October 2023
- Case
Vida Health: Transforming Chronic Disease Treatment
By: William Sahlman and Nicole Tempest Keller
San Francisco based Vida Health, founded by Stephanie Tilenius, former vice president of Commerce and Payments at Google, was a B2B digital health startup focused on the treatment of cardiometabolic conditions, such as diabetes and obesity. Its innovative digital...
View Details
- July 2023
- Teaching Note
Hello Heart: The Next Generation of Chronic Disease Management Apps
By: Ariel Dora Stern and Kumba Sennaar
Teaching Note for HBS Case No. 622-061.
View Details
- 2023
- Article
Building the Business Case for an Inclusive Approach to Digital Health Measurement with a Web App (Market Opportunity Calculator): Instrument Development Study
By: Mitchell Tang, Yashoda Sharma, Jennifer C. Goldsack and Ariel Dora Stern
Background: The use of digital health measurement tools has grown substantially in recent years. However, there are concerns that the promised benefits from these products will not be shared equitably. Underserved populations, such as those with lower education and...
View Details
Keywords:
Demographics;
Product Development;
Health Care and Treatment;
Medical Devices and Supplies Industry
Tang, Mitchell, Yashoda Sharma, Jennifer C. Goldsack, and Ariel Dora Stern. "Building the Business Case for an Inclusive Approach to Digital Health Measurement with a Web App (Market Opportunity Calculator): Instrument Development Study." JMIR Formative Research 7 (2023).
- June 2023
- Case
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.
This case...
View Details
- June 2023
- Case
Verve Therapeutics: Taking DNA Editing to Heart
By: Shikhar Ghosh and Shweta Bagai
Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing...
View Details
Keywords:
AI;
Genetic Engineering;
Medicine;
Health Care and Treatment;
Genetics;
Innovation Strategy;
Business and Stakeholder Relations;
Medical Specialties;
Innovation and Invention;
Entrepreneurship;
Biotechnology Industry
Ghosh, Shikhar, and Shweta Bagai. "Verve Therapeutics: Taking DNA Editing to Heart." Harvard Business School Case 823-113, June 2023.
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,...
View Details
Keywords:
Health Care and Treatment;
Business Model;
Leadership;
Pharmaceutical Industry;
Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (A): Reimagining Medicine." Harvard Business School Case 723-443, May 2023. (Revised June 2023.)
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,...
View Details
Keywords:
Health Care and Treatment;
Business Model;
Production;
Business Strategy;
Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,...
View Details
Keywords:
Health Testing and Trials;
Health Care and Treatment;
Business Model;
Problems and Challenges;
Pharmaceutical Industry;
Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- January 2023
- Supplement
Apple: Privacy vs. Safety (B)
By: Henry McGee, Nien-hê Hsieh and Christian Godwin
In 2020, as the COVID-19 pandemic swept across the globe, Apple and Google partnered to develop a contact tracing application that would collect information about users infected with the disease and notify those who they had been in contact with. While Apple/Google’s...
View Details
Keywords:
Iphone;
Encryption;
Data Privacy;
Customers;
Customer Focus and Relationships;
Decision Making;
Ethics;
Values and Beliefs;
Globalized Firms and Management;
Government and Politics;
Health;
Health Pandemics;
Leadership;
Markets;
Safety;
Social Issues;
Information Technology;
Telecommunications Industry;
Technology Industry;
Consumer Products Industry;
Electronics Industry;
Health Industry;
United States;
Europe
McGee, Henry, Nien-hê Hsieh, and Christian Godwin. "Apple: Privacy vs. Safety (B)." Harvard Business School Supplement 323-066, January 2023.
- January 2023
- Supplement
The END Fund (B)
By: V. Kasturi Rangan and Courtney Han
Founded in 2012, the END fund focused on eliminating five Neglected Tropical Diseases that accounted for 80% of the tropical diseases affecting nearly 1.5 billion people worldwide. Its roughly $25 million/year annual budget was fully committed when it got news that the...
View Details
Keywords:
Health Disorders;
Investment Funds;
Global Range;
Nonprofit Organizations;
Resource Allocation;
Decisions;
Health Care and Treatment;
Mission and Purpose
Rangan, V. Kasturi, and Courtney Han. "The END Fund (B)." Harvard Business School Supplement 523-064, January 2023.
- January 2023
- Case
The END Fund: To Eliminate Neglected Tropical Diseases
By: V. Kasturi Rangan and Courtney Han
Founded in 2012, the END fund focused on eliminating five Neglected Tropical Diseases that accounted for 80% of the tropical diseases affecting nearly 1.5 billion people worldwide. Its roughly $25 million/year annual budget was fully committed when it got news that the...
View Details
Keywords:
Nonprofit Organizations;
Health Disorders;
Health Care and Treatment;
Resource Allocation;
Global Range;
Decisions;
Investment Funds
Rangan, V. Kasturi, and Courtney Han. "The END Fund: To Eliminate Neglected Tropical Diseases." Harvard Business School Case 523-063, January 2023.
- 2022
- Article
Investigating the Association Between Telemedicine Use and Timely Follow-Up Care After Acute Cardiovascular Hospital Encounters
By: Mitchell Tang, A Jay Holmgren, Erin E. McElrath, Ankeet S. Bhatt, Anubodh S. Varshney, Simin Gharib Lee, Muthiah Vaduganathan, Dale S. Adler and Robert S. Huckman
Background: Telemedicine use increased dramatically during the COVID-19 pandemic; however, questions remain as to how telemedicine use impacts care.
Objectives: The purpose of this study was to examine the association of increased telemedicine use on rates of... View Details
Objectives: The purpose of this study was to examine the association of increased telemedicine use on rates of... View Details
Keywords:
Health Care;
Telemedicine;
Health Care and Treatment;
Outcome or Result;
Behavior;
Health Industry;
United States
Tang, Mitchell, A Jay Holmgren, Erin E. McElrath, Ankeet S. Bhatt, Anubodh S. Varshney, Simin Gharib Lee, Muthiah Vaduganathan, Dale S. Adler, and Robert S. Huckman. "Investigating the Association Between Telemedicine Use and Timely Follow-Up Care After Acute Cardiovascular Hospital Encounters." JACC: Advances 1, no. 5 (2022).
- October 2022 (Revised May 2023)
- Case
Podimetrics: Next Steps for Diabetes Cases
By: Regina E. Herzlinger and Ben Creo
Podimetrics, a virtual care management company treating adults with acute diabetes, sat at the intersection of medical device technology, digital health, and health services. Its SmartMat had demonstrated that it could help prevent amputations and that people with...
View Details
Keywords:
Health Care;
Health Care Delivery;
Health Care Entrepreneurship;
Health Care Outcomes;
Diabetes;
Chronic Disease;
Chronic Illness;
Health Care and Treatment;
Health Disorders;
Medical Specialties;
Technological Innovation;
Innovation Strategy;
Product Development;
Business Model;
Customer Focus and Relationships;
Medical Devices and Supplies Industry;
Health Industry
- 2022
- Book
Healthy Buildings: How Indoor Spaces Can Make You Sick—or Keep You Well
By: Joseph G. Allen and John D. Macomber
For too long we’ve designed buildings that haven’t focused on the people inside—their health, their ability to work effectively, and what that means for the bottom line. An authoritative introduction to a movement whose vital importance is now all too clear, Healthy...
View Details
Allen, Joseph G., and John D. Macomber. Healthy Buildings: How Indoor Spaces Can Make You Sick—or Keep You Well. Revised and updated edition, Cambridge, MA: Harvard University Press, 2022.
- 2022
- Article
Rapid Growth of Remote Patient Monitoring Is Driven by a Small Number of Primary Care Providers
By: Mitchell Tang, Ateev Mehrotra and Ariel Dora Stern
Growing enthusiasm for remote patient monitoring has been motivated by the hope that it can improve care for patients with poorly controlled chronic illness. In a national commercially insured population in the U.S., we found that billing for remote patient monitoring...
View Details
Keywords:
Remote Monitoring;
Medical Billing;
Health Care Costs;
Telehealth;
Diabetes;
Chronic Disease;
Insurance Claims;
Diseases;
Primary Care Providers;
COVID-19 Pandemic;
Health Care and Treatment;
Insurance;
Cost;
Health Industry;
United States
Tang, Mitchell, Ateev Mehrotra, and Ariel Dora Stern. "Rapid Growth of Remote Patient Monitoring Is Driven by a Small Number of Primary Care Providers." Health Affairs 41, no. 9 (2022): 1248–1254.
- September 2022
- Article
Trends in Remote Patient Monitoring Use in Traditional Medicare
By: Mitchell Tang, Carter Nakamoto, Ariel Dora Stern and Ateev Mehrotra
Remote patient monitoring (RPM), the collection by patients of physiological measurements that are automatically sent to their health care practitioners, has been touted as a promising tool for improving chronic disease management. Interest in RPM has grown because of...
View Details
Tang, Mitchell, Carter Nakamoto, Ariel Dora Stern, and Ateev Mehrotra. "Trends in Remote Patient Monitoring Use in Traditional Medicare." JAMA Internal Medicine 182, no. 9 (September 2022): 1005–1006.
- July 2022
- Teaching Plan
Wellthy: The Economics of Caring
By: Brian Trelstad
Teaching Plan for HBS Case No. 320-028. In 2014, Lindsay Jurist-Rosner (MBA ’09) founded Wellthy, a B2C business that coordinates care for working professionals seeking help to support loved ones with chronic diseases or aging parents. With personal experience as a...
View Details
- 2022
- Report
The First Four Healthy Building Strategies Every Building Should Pursue to Reduce Risk from COVID-19
By: Joseph G. Allen, Emily Jones, Marissa V. Rainbolt, Linsey C. Marr, David Michaels, Leslie R. Cadet, Shelly L. Miller, Meira Levinson, Lidia Morawska, Richard L. Corsi, Nira R. Pollock, Yuguo Li, Alasdair P.S. Munro, Kelly Grier, Qingyan Chen, John D. Macomber and Xiaodong Cao
Understanding of the most probable transmission routes and identifying the risk environments for disease spread should always be among the first critical steps in the response to future disease threats. This is one of the most vital public health lessons of the...
View Details
Keywords:
Health Pandemics;
Buildings and Facilities;
Risk and Uncertainty;
Health Industry;
Education Industry;
Real Estate Industry
Allen, Joseph G., Emily Jones, Marissa V. Rainbolt, Linsey C. Marr, David Michaels, Leslie R. Cadet, Shelly L. Miller, Meira Levinson, Lidia Morawska, Richard L. Corsi, Nira R. Pollock, Yuguo Li, Alasdair P.S. Munro, Kelly Grier, Qingyan Chen, John D. Macomber, and Xiaodong Cao. "The First Four Healthy Building Strategies Every Building Should Pursue to Reduce Risk from COVID-19." Report, Lancet COVID-19 Commission, Task Force on Safe School, Safe Work, Safe Travel, July 2022. (COVID-19 Commission.)
- Article
Policies to Influence Perceptions about COVID-19 Risk: The Case of Maps
By: Claudia Engel, Jonathan Rodden and Marco Tabellini
Choropleth disease maps have become an important tool for informing the public about the risks posed by COVID-19. In a survey conducted in the U.S. state of Georgia in June 2020, we randomly assigned respondents to view either of two maps. The first one reported...
View Details
Engel, Claudia, Jonathan Rodden, and Marco Tabellini. "Policies to Influence Perceptions about COVID-19 Risk: The Case of Maps." Science Advances 8, no. 11 (March 18, 2022).
- February 2022 (Revised November 2022)
- Case
Nuritas
By: Mitchell Weiss, Satish Tadikonda, Vincent Dessain and Emer Moloney
Nora Khaldi had built a technology “to unlock the power of nature” in the service of extending human lifespan and improving health, and now in April 2020 was debating telling her Board of Directors she wanted to put on ice some of her discoveries. Nuritas, the company...
View Details
Keywords:
Cash Burn;
Cash Flow Analysis;
Pharmaceutical Companies;
Founder;
Artificial Intelligence;
AI;
Entrepreneurship;
Health Testing and Trials;
Health Care and Treatment;
Decision Making;
Market Entry and Exit;
AI and Machine Learning;
Pharmaceutical Industry
Weiss, Mitchell, Satish Tadikonda, Vincent Dessain, and Emer Moloney. "Nuritas." Harvard Business School Case 822-080, February 2022. (Revised November 2022.)